Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Layth1990on Dec 24, 2019 7:16pm

323 Views

Post# 30489083

Price after enrollment and study completion

I was wondering when this stock will go high. We have all the potentional and in my opinion it's even better than other pharmas. Mdna doubled its stock price between yesterday and today. LMNL went from 7 to 21 then setteled today at 13. Both went up without any recent news. I dont know why this stock is stuck and going even down and not up. In your opinion What will be the price after enrollment is completed and successful comletion ?

Bullboard Posts

The top 10 Canadian medical stocks